GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (TSX:AEZS) » Definitions » Inventory Turnover
中文

AEterna Zentaris (TSX:AEZS) Inventory Turnover

: 0.69 (As of Dec. 2023)
View and export this data going back to 1995. Start your Free Trial

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. AEterna Zentaris's Cost of Goods Sold for the three months ended in Dec. 2023 was C$0.07 Mil. AEterna Zentaris's Average Total Inventories for the quarter that ended in Dec. 2023 was C$0.11 Mil. AEterna Zentaris's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.69.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. AEterna Zentaris's Days Inventory for the three months ended in Dec. 2023 was 132.50.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. AEterna Zentaris's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.65.


AEterna Zentaris Inventory Turnover Historical Data

The historical data trend for AEterna Zentaris's Inventory Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEterna Zentaris Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventory Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.57 3.68 1.92 1.05 1.49

AEterna Zentaris Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Inventory Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.22 0.08 0.85 0.12 0.69

AEterna Zentaris Inventory Turnover Calculation

AEterna Zentaris's Inventory Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Inventory Turnover (A: Dec. 2023 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (A: Dec. 2023 ) / ((Total Inventories (A: Dec. 2022 ) + Total Inventories (A: Dec. 2023 )) / count )
=0.298 / ((0.311 + 0.089) / 2 )
=0.298 / 0.2
=1.49

AEterna Zentaris's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover (Q: Dec. 2023 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (Q: Dec. 2023 ) / ((Total Inventories (Q: Sep. 2023 ) + Total Inventories (Q: Dec. 2023 )) / count )
=0.073 / ((0.123 + 0.089) / 2 )
=0.073 / 0.106
=0.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AEterna Zentaris  (TSX:AEZS) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

AEterna Zentaris's Days Inventory for the three months ended in Dec. 2023 is calculated as:

Days Inventory =Average Total Inventories (Q: Dec. 2023 )/Cost of Goods Sold (Q: Dec. 2023 )*Days in Period
=0.106/0.073*365 / 4
=132.50

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

AEterna Zentaris's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=0.106 / 0.162
=0.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.


AEterna Zentaris Inventory Turnover Related Terms

Thank you for viewing the detailed overview of AEterna Zentaris's Inventory Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


AEterna Zentaris (TSX:AEZS) Business Description

Traded in Other Exchanges
Address
222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7
AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.